PKCd germline variants and genetic deletion in mice augment antitumor immunity through regulation of myeloid cells.
PKCd germline variants and genetic deletion in mice augment antitumor immunity through regulation of myeloid cells. Cancer Immunol Res. 2025 Jan 14.
PMID: 39808445Targeting molecular pathways to control immune checkpoint inhibitor toxicities.
Targeting molecular pathways to control immune checkpoint inhibitor toxicities. Trends Immunol. 2025 Jan; 46(1):61-73.
PMID: 39732529Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan; 637(8048):1218-1227.
PMID: 39663448Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy.
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy. J Immunother Cancer. 2024 Oct 26; 12(10).
PMID: 39461876Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy.
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024 Jun 10; 42(6):1032-1050.e10.
PMID: 38759656Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy.
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 05 28; 43(5):114141.
PMID: 38656869Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulation.
Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulation. bioRxiv. 2024 Apr 12.
PMID: 38644995Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). J Transl Med. 2023 07 28; 21(1):508.
PMID: 37507765Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. J Immunother Cancer. 2023 06; 11(6).
PMID: 37385724Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.
View All Publications
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition. Eur J Cancer. 2023 08; 189:112923.
PMID: 37301715

People
Thomas F. Gajewski, MD PhD
-
AbbVie Foundation Professor of Pathology
Professor of Ben May Department of Cancer Research
Professor of Medicine
Committee on Cancer Biology
Committee on Clinical Pharmacology and Pharmacogenomics - Clinical Interests: Immunotherapy, Melanoma
- Websites: Research Network Profile
- Contact: tgajewsk@medicine.bsd.uchicago.edu
- Graduate Programs: Cancer Biology, UChicago Biosciences, Committee on Immunology